Results 271 to 280 of about 1,501,166 (361)

Moulage: "Lupus Erythematosus"

Dermatology Practical & Conceptual, 2011
Beatrix Patzak
doaj   +1 more source

Pathologic complete response to pralsetinib in stage IV RET-positive non-small cell lung cancer: A case report. [PDF]

Respir Med Case Rep
Chen X, Wang G, Zhang J, Bao W, Cai J, Guo J, Lv T, Ye M.   +7 more
europepmc   +1 more source

Evaluation of Arginase Activity in Normal Epidermal Tissue and Pathological Stratum Corneum11From the Dermatology Service, General Medicine Branch, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare, Bethesda, Maryland.

, 1958
Simon Rothberg, Eugene J. Van Scott, S.L. Newberry   +2 more
openalex   +1 more source

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

Molecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger, Dorin Bar‐Ziv, Harriet Kluger   +2 more
wiley   +1 more source

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. [PDF]

Nat Med
Dummer R, Robert C, Scolyer RA, Taube JM, Tetzlaff MT, Menzies AM, Hill A, Grob JJ, Portnoy DC, Lebbe C, Khattak MA, Cohen J, Bar-Sela G, Mehmi I, Shapira-Frommer R, Meyer N, Webber AL, Ren Y, Fukunaga-Kalabis M, Krepler C, Long GV.   +20 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Bone mineral density as potential individual prognostic biomarker in patients with neurosurgically treated spinal metastasis. [PDF]

J Cancer Res Clin Oncol
Asoglu H, Lampmann T, Jaber M, Khalafov L, Dittmer J, Ilic I, Gielen GH, Toma M, Vatter H, Bendella Z, Schneider M, Schmeel C, Hamed M, Banat M.   +13 more
europepmc   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Neoadjuvant treatment and premastectomy radiotherapy: oncological and surgical outcomes. [PDF]

Gland Surg
Bannier M, Cohen M, Tallet A, de Nonneville A, Houvenaeghel G.   +4 more
europepmc   +1 more source

MIF as an oncogenic driver of low‐heterogeneity melanomas

Molecular Oncology, EarlyView.
Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran, Gabriela Athziri Sánchez‐Zuno, Rajan P. Kulkarni, Harriet M. Kluger, Richard Bucala   +4 more
wiley   +1 more source